Serrita J, et al. - Researchers conducted the first study to date examining glycine, an agonist of the glycine B co-agonist site of the N-methyl-D-aspartate receptor, for its effectiveness on alcohol consumption and cravings, as well as on negative symptoms in schizophrenia. For 12 weeks, 0.8 g/kg glycine or matching placebo (provided in bottles with mixed in solution) was provided to participants (N=20) each week. In line with the largest trial of glycine treatment in schizophrenia, this study revealed no beneficial effect of glycine over placebo. Because of more severe psychopathology, it seems more difficult to treat diagnosed schizophrenia and alcohol dependence.